Vaxxa AB
Vaxxa AB operates an auction platform, vaxxa.se, which offers private individuals and companies to sell and buy used objects in vehicles, machinery, and construction industry. The company was formerly known as Augeo Group AB and changed its name to Vaxxa AB in July 2023. Vaxxa AB was incorporated in 2015 and is based in Stockholm, Sweden.
Vaxxa AB (7WA0) - Total Liabilities
Latest total liabilities as of June 2025: €2.05 Million EUR
Based on the latest financial reports, Vaxxa AB (7WA0) has total liabilities worth €2.05 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaxxa AB - Total Liabilities Trend (2021–2024)
This chart illustrates how Vaxxa AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaxxa AB Competitors by Total Liabilities
The table below lists competitors of Vaxxa AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Correlate Infrastructure Partners Inc
OTCQB:CIPI
|
USA | $9.91 Million |
|
Modern Healthcare Technology Holdings Limited
F:M3L
|
Germany | €362.05 Million |
|
Taoping Inc
NASDAQ:TAOP
|
USA | $15.84 Million |
|
PFEIFFER VACU TECH
MU:PFV
|
Germany | €403.52 Million |
|
Carmat SA
F:CXT
|
Germany | €93.56 Million |
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
USA | $1.15 Million |
|
PROGRESSIVE (OHIO) - Dusseldorf Stock Exchang
DU:PGV
|
Germany | €78.04 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Vaxxa AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxxa AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxxa AB (2021–2024)
The table below shows the annual total liabilities of Vaxxa AB from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €8.04 Million | +4.08% |
| 2023-12-31 | €7.72 Million | +116.45% |
| 2022-12-31 | €3.57 Million | +114.81% |
| 2021-12-31 | €1.66 Million | -- |